Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Omega-3 fatty acids for bipolar disorder
Your Article Summary
Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective
Cost Effectiveness and Resource Allocation, 05/11/09
Scherbaum WA et al. - The findings of modelling analysis indicated that, for patients with a history of macrovascular disease, addition of pioglitazone to existing therapy reduces the long-term cumulative incidence of diabetes-complications at a cost that would be considered to represent good value for money in the German setting.
Today in Economics of Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
Medicare cracks down on false claims
Medical Economics, 11/02/09
2009 earnings survey: How do you compare
Medical Economics, 09/29/09
How sensitive is physician performance to alternative compensation schedules? Evidence from a large network of primary care clinics
Health Economics, 10/29/09
Sponsor
Article Search
Sponsor


See Latest Articles


